Is MannKind Corporation’s Afrezza Turning Into A Dud?


Sanofi reported in April that MannKind’s inhaled insulin drug Afrezza generated only $1.1 million in sales in the first two months of its launch. The Valencia, California-based company has argued that its marketing partner Sanofi was conducting a “slow launch on purpose.” The French drugmaker has also said in the past that the initial rollout of Afrezza was “targeted and focused” on raising awareness about the treatment and its appropriate usage.

Afrezza prescriptions even lower than Exubera?

Now Adam Feuerstein of The Street says that Afrezza prescriptions have been even lower than Pfizer’s Exubera, which itself was a failure. Pfizer had to withdraw Exubera from the market due to poor sales. Feuerstein’s statement is based on data from Bloomberg and IMS Health. He says Afrezza is having “no impact at all” on market share of rival injectable insulins. So, is Afrezza turning into a dud? It’s probably too early to say that.

MannKind’s drug has only 0.10% market share after five months of launch despite the backing on Sanofi, which has extensive expertise in diabetes treatment. The U.S. biopharma company is looking to succeed where the awkwardly large Exubera failed. Afrezza is a convenient inhaled insulin that, despite regulatory concerns, has received rave reviews from early adopters.

Consistency is what makes the top 50 best-performing hedge funds so strong

Every month and quarter, multiple reports on average hedge fund returns are released from several sources. However, it can be difficult to sift through the many returns to uncover the most consistent hedge funds. The good news is that Eric Uhlfelder recently released his "2022 Survey of the Top 50 Hedge Funds," which ranks the Read More

MannKind witnesses steep decline in short interest

RBC Capital Markets and Jefferies, two research firms that have been keeping close tabs on Afrezza prescriptions, remain bullish. Jefferies said last month that Afrezza sales would pick up in the third quarter as Sanofi and MannKind launch a massive direct to consumer (DTC) advertising campaign. Earlier this week, RBC Capital Markets reaffirmed its Outperform rating on the stock with $10 price target. Jefferies has a $9 price target.

Meanwhile, MannKind is planning to triple the production capacity at its Danbury plant to meet the potential demand.  Short interest in MannKind fell sharply from 131.15 million shares on May 29 to 120.42 million on June 15, the latest date for which data is available. It represents 8.2% decline in short interest. Based on the average daily trading volume of 14.89 million shares, it would take eight days to cover the short positions, down from 12.36 days on May 29th.

Updated on

No posts to display


  1. As far as I can tell, no authentic reporting done here. Consistently negative articles on Mannkind. I wonder if it’s related to the high short interest? Hmmm???? Thanks Mr. Shill.

  2. just the fact that he quoted Feuerstein shows that the author hasn’t a clue what he’s talking about. Please do some research on the topic before writing an article. It’s embarrassing for you.

  3. Boy the “shorts” are coming out of the woodwork now–yesterday (June 30) it was Adam Feuerstein (of “The Street”) with a completely nonsensical article–now this one–tell me-has the advertisement campaign for Afrezza even launched yet??? have you spoken to all those diabetics who are currently using Afrezza and asked them if they have ever had better glycemic control? lower A1C levels? life threatening hypoglycemic “lows”–May I ask you don’t write an article unless you have something intelligent to say

Comments are closed.